NRx Pharmaceuticals, Inc. (NRXP) Tops Q3 EPS by 4c

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) reported Q3 EPS of ($0.07), $0.04 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on NRx Pharmaceuticals, Inc. (NRXP) click here.

You May Also Be Interested In

• Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
• BridgeBio Oncology Therapeutics, In (BBOT) PT Lowered to $15 at Stifel
• Needham on Barnes & Noble Education (BNED): 'we remain buyers on the weakness'